Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine Kinases

Abstract

Constitutive activation of receptor tyrosine kinases (RTKs) is a frequent event in human cancer cells. Activating mutations in Fms-like tyrosine kinase 3 (FLT-3), notably, internal tandem duplications in the juxtamembrane domain (FLT-3 ITD), have been causally linked to acute myeloid leukemia. As we describe here, FLT-3 ITD exists predominantly in an immature, underglycosylated 130-kDa form, whereas wild-type FLT-3 is expressed predominantly as a mature, complex glycosylated 150-kDa molecule. Endogenous FLT-3 ITD, but little wild-type FLT-3, is detectable in the endoplasmic reticulum (ER) compartment. Conversely, cell surface expression of FLT-3 ITD is less efficient than that of wild-type FLT-3. Inhibition of FLT-3 ITD kinase by small molecules, inactivating point mutations, or coexpression with the protein-tyrosine phosphatases (PTPs) SHP-1, PTP1B, and PTP-PEST but not RPTPα promotes complex glycosylation and surface localization. However, PTP coexpression has no effect on the maturation of a surface glycoprotein of vesicular stomatitis virus. The maturation of wild-type FLT-3 is impaired by general PTP inhibition or by suppression of endogenous PTP1B. Enhanced complex formation of FLT-3 ITD with the ER-resident chaperone calnexin indicates that its retention in the ER is related to inefficient folding. The regulation of RTK maturation by tyrosine phosphorylation was observed with other RTKs as well, defines a possible role for ER-resident PTPs, and may be related to the altered signaling quality of constitutively active, transforming RTK mutants.

ACKNOWLEDGMENTS

We are grateful to S. Scholl for providing THP-1 and MV4-11 cells as well as for help with FACS analysis. We thank W. Birchmeier, L. Claesson-Welsh, D. Fujita, S. Gutkind, C. H. Heldin, L. Rönnstrand, M. Tremblay, and A. Ullrich for providing various cDNAs and H. Keilhack, M. O'Farrel, and G. Nolan for providing other reagents and tools.

This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB604, A1, and Bo 1043/4-3 to F.-D.B. and Se600/2-3 to H.S.), from the Deutsche Krebshilfe (10-2100-Do2 to F.-D.B.), and from the IZKF Münster (to H.S.).